Despite recent disappointment with antiretroviral agents, investigators continue to examine combination therapy with agents that target the same or different stages of the HIV life cycle. Initial studies suggest that when therapy is started early in the course of infection, certain combinations may be better than single-drug regimens in reducing viral burden and delaying the onset of drug resistance.